Boehringer Ingelheim

CureVac secured Gates Foundation backing

CureVac to build plant with Gates Foundation money

By Gareth Macdonald

CureVac will build a manufacturing facility for mRNA vaccines after a $52m (€46m)  Gates Foundation investment that also brings an IPO one step closer according to majority shareholder Dietmar Hopp.

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

By Zachary Brennan

Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer.